EU Grants Conditional Authorization for Zemcelpro Stem Cell Therapy

Published on: ExCellThera / Cordex Biologics

The European Commission has conditionally authorized Zemcelpro (UM171 Cell Therapy), the first cell therapy option for adults with blood cancers who lack suitable donor cells for transplantation. Zemcelpro uses cord blood–derived stem cells expanded with UM171 technology, offering a potentially life-saving transplant option for patients facing critical unmet needs. The approval could increase access across Europe for thousands of leukemia and myelodysplastic syndrome patients.

👉 Read the full article: Zemcelpro Receives EC Authorization as First Cell Therapy for Patients Without Donor Cells

Disclaimer:

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.